Adia Med Inc. Engages Lucosky Brookman LLP as Legal Counsel for Planned NASDAQ Uplisting
Rhea-AI Summary
Adia Med (OTCQB: ADIA) announced it has entered into an engagement letter with Lucosky Brookman to serve as legal counsel for the company’s planned uplisting from the OTC Markets to the NASDAQ Capital Market.
According to Adia Med, Lucosky Brookman will handle preparation, review and filing of a Form S-1 registration statement with the SEC, related due diligence, responses to SEC comments and amendments, and the company’s application to list its securities on a nationally recognized exchange, including Nasdaq. Following any Nasdaq listing, Lucosky Brookman is also expected to provide ongoing SEC compliance support, such as periodic Exchange Act, Section 16 and basic Form 8-K filings, and review of basic press releases.
Positive
- None.
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Winter Park, Florida--(Newsfile Corp. - August 24, 2026) - Adia Med Inc. (OTCQB: ADIA) today announced that it has entered into an engagement letter with Lucosky Brookman LLP ("Lucosky Brookman") to act as legal counsel in connection with the Company's planned uplisting from the OTC Markets to the NASDAQ Capital Market.
Lucosky Brookman LLP
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10520/310842_screenshot_lb_15_years.jpg
Under the engagement letter, Lucosky Brookman will provide services that include the preparation and/or review and filing of a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (the "SEC"), conducting necessary due diligence related to the registration statement, preparation and filing of responses to SEC comments and any related amendments, preparation and filing of the Company's application for listing of its securities on a nationally recognized securities exchange (including responses to comments and amendments), and assisting with general corporate matters related to the registration statement and listing application.
Upon the Company listing its securities on Nasdaq, Lucosky Brookman will also provide certain ongoing SEC compliance services, including periodic Exchange Act filings, Section 16 filings, basic Form 8-K filings, and review of basic press releases.
Lucosky Brookman LLP is a national corporate law firm founded in 2011 that specializes in capital markets, securities, corporate finance, and related matters for small- and middle-market companies. With more than 70 attorneys and offices across New York, New Jersey, Pennsylvania, Texas, Washington, D.C., and other locations, the firm advises domestic and international clients on public offerings, registration statements, uplistings from the OTC Markets to NASDAQ or the NYSE, PIPEs, mergers and acquisitions, and ongoing SEC compliance. Known for its relationship-focused, results-driven approach and deep experience guiding emerging-growth companies through complex securities transactions, Lucosky Brookman has grown from a boutique corporate and securities practice into a full-service firm that also handles commercial litigation, insurance coverage, and regulatory matters.
Larry Powalisz, Chief Executive Officer of Adia Med Inc., stated: "Engaging Lucosky Brookman represents an important step in our efforts to uplist to the Nasdaq exchange. We look forward to working with their experienced securities team."
For questions, inquiries, or additional information, please contact Larry Powalisz at ceo@adiamed.com or by phone at 321-231-2843.
About Adia Med Inc.
Adia Med Inc. (OTCQB: ADIA), headquartered in Winter Park, Florida, is a regenerative medicine company built around active, IRB-approved stem cell therapy studies. Through its Adia Med clinics, the company delivers stem cell treatments alongside complementary services like platelet-rich plasma (PRP), therapeutic plasma exchange (TPE), and autologous hematopoietic stem cell transplantation (aHSCT), supported by multiple Institutional Review Board (IRB)-approved clinical studies, The current studies are targeting autism spectrum disorder, chronic kidney disease, and lower back pain, with more planned for 2026. Its Adia Labs division manufactures regenerative products (AdiaVita, AdiaLink) that supply this clinical work.
Adia Labs generates revenue by manufacturing and selling regenerative products (AdiaVita and AdiaLink) to Adia Med clinics and external providers. Adia Med clinics generate revenue through patient treatments (stem cell therapies, PRP, TPE, and aHSCT). Additional revenue comes from the company's
Website: www.adiamed.com
Website: www.adialabs.com
Website: www.cementfactory.co
Twitter (X): @adia_med
Instagram: @adia_med
Facebook: @adia_med
Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/310842